Draft:ISA Pharmaceuticals B.V.
| Submission declined on 1 November 2023 by DoubleGrazing (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 21 March 2023 by Jamiebuba (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. | |
Comment: Not only is there no real evidence of notability, there is nothing in the article which tells us why this should be included in a global encyclopaedia. Simply existing isn't a sufficient reason. DoubleGrazing (talk) 12:48, 1 November 2023 (UTC)
ISA Pharmaceuticals B.V. is an immunotherapy company with headquarters in Oegstgeest, Netherlands.[1][2] The company was founded by Aglaia Oncology Fund and Professor Cornelis Melief in 2004.[3][4]
The company’s research and development centres around its Synthetic Long Peptide (SLP) concept[4] and its AMPLIVANT technology.[5][6]
Management
In January 2016, Gerben Moolhuizen was appointed as Chief Business Development Officer[7] and promoted to Chief Executive Officer in May 2018, taking over the position from Ronald Loggers, who had served as the company's CEO since 2013.[8]
History
ISA Pharmaceuticals was founded in 2004 by Aglaia Oncology Fund[9] and Cornelis “Kees” Melief.[10]
The company has research collaborations with the Leiden University Medical Center,[11] and Erasmus Medical Center Rotterdam.[12]
References
- ^ Laws, Liza (2022-11-08). "ISA Pharmaceuticals' Amplivant adjuvant boosts immune response in SLP immunotherapy". Labiotech.eu. Retrieved 2023-07-09.
- ^ kgi-admin (2023-03-02). "Peltopepimut-s by ISA Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval". Pharmaceutical Technology. Retrieved 2023-07-09.
- ^ "company". ISA Therapeutics BV. Retrieved 2022-12-12.
- ^ a b Funds, Aglaia Oncology. "FDA grants ISA Pharmaceuticals Orphan Drug Designation for the treatment of Vulvar Intraepithelial Neoplasia with its lead product ISA-HPV-SLP®". Aglaia Oncology Funds. Retrieved 2022-12-12.
- ^ Pinching, John (2022-04-14). "ISA Pharmaceuticals announce new trial testing technology for cancers". PharmaTimes. Retrieved 2022-12-12.
- ^ "Novel IO Vaccine Induces Immune Response HPV16-Positive Tumors". Targeted Oncology. 2022-11-09. Retrieved 2023-07-09.
- ^ Gibney, Michael (2016-01-08). "ISA Pharmaceuticals Appoints Gerben Moolhuizen As Chief Business Development Officer". Fierce Biotech. Retrieved 2022-12-12.
- ^ ISA_Pharma_beheer_2018 (2018-05-23). "ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer". ISA Therapeutics BV. Retrieved 2022-12-12.
{{cite web}}: CS1 maint: numeric names: authors list (link) - ^ Funds, Aglaia Oncology. "ISA Pharmaceuticals Secures EUR 8 Million Funding". Aglaia Oncology Funds. Retrieved 2022-12-12.
- ^ "Cornelis J.M. Melief, MD, PhD". Cancer Research Institute. Retrieved 2022-12-12.
- ^ "Therapeutic vaccine boosts survival rate in cervical cancer patients". Leiden University. Retrieved 2022-12-12.
- ^ "ISA Pharmaceuticals, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline – 1stOncology™: Cancer Intelligence Service". 2021-07-20. Retrieved 2023-07-09.